JINLING PHARM.: Fuzhou Meifeng Pharmaceutical Factory's hydrolyzed protein injection has received re-registration approval

On August 20, 2025, JINLING PHARM. announced that its subsidiary Fuzhou Meifeng Pharmaceutical Factory recently received the re-registration approval notice for hydrolyzed protein injection from the Fujian Provincial Drug Administration. The drug acceptance number is CYHZ2514512 Min, with a specification of 500ml:25g, classified as a chemical drug. Due to long-term suspension of production, resuming production requires an on-site inspection application to the provincial drug administration, and the drug can only be marketed after passing the inspection and sampling. Hydrolyzed protein injection is used for severe amino acid deficiency and hypoproteinemia. The re-registration is beneficial for the drug's production and sales recovery, but it has no significant impact on recent performance, and the production and sales of the drug are subject to uncertainties influenced by policies, market conditions, and other factors, reminding investors to pay attention to risks